Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

ANRO vs EVGN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ANRO Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 6–1 Matrix Metrics)

ANRO Overall Winner 6-Pillar Tally: ANRO 3 – 1 EVGN (2 Tie) Matrix Metrics: ANRO 6 – 1 EVGN

As of Nov 17, 2026, Alto Neuroscience Inc. (ANRO) is the stronger overall head-to-head candidate over Evogene Ltd. (EVGN) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). ANRO carries a Unified Composite Score of 34.3/100 (SELL) at $24.91 (N/M Forward P/E, 0.0% operating margin), whereas EVGN carries 44.1/100 (HOLD) at $0.34 (N/M Forward P/E, -858.2% operating margin).

  • Composite vs. Pillar Nuance: While EVGN currently prints a higher short-term Unified Composite Score (44.1/100 HOLD vs. ANRO 34.3/100 SELL), ANRO captures the overall institutional head-to-head verdict (6–1 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -858.2% operating margin) and revenue trajectory (+0.0% vs. -60.7% YoY).
  • Technical & Structure Timing Caution: ANRO is currently in a Breakdown options structure phase (RSI 47.4); meanwhile EVGN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ANRO vs EVGN
ANRO NYSE Head-to-Head Winner
Alto Neuroscience Inc.
Pharmaceutical Preparations
$24.91
-8.15% 1D
Market Cap $1.1B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 2.03β · 94% Vol
Unified Composite Score
34.3 / 100 SELL
Tech 15.0 Fund 38.0 Flow 64.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 47.4 · SMA20: $24.86 · SMA50: $25.98
EVGN NASDAQ
Evogene Ltd.
Agricultural Chemicals
$0.34
-13.17% 1D
Market Cap $6.0M
TTM Revenue $1.7M
Forward P/E N/M
Beta / 30D Vol 1.37β · 138% Vol
Unified Composite Score
44.1 / 100 HOLD
Tech 42.0 Fund 44.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -17.2%), weak momentum, RSI 44
RSI-14: 44.5 · SMA20: $0.36 · SMA50: $0.40

6-Pillar Scorecard Institutional Category Breakdown (ANRO 3 – 1 EVGN)

Columns: Metric · ANRO · EVGN
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale ANRO
Revenue Growth (YoY) +0.0% -60.7%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $1.7M
Market Cap $1.1B $6.0M
3. Profitability & Quality ANRO
Gross Margin N/A -67.6%
Operating Margin 0.0% -858.2%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -46.7% -182.8%
4. Balance Sheet & Cash Flow EVGN
Cash Generation (TTM) -$80M -$11M
Cash Flow Margin N/A N/A
Net Cash / Leverage $301M Net Cash $6.5M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ANRO
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 82.2% (9th %ile) N/A (N/A)
Put/Call OI Skew 0.04x (Call-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ANRO (6) vs EVGN (1)
Institutional Metric ANRO EVGN Criterion Row Edge
Market Capitalization
Scale
$1.1B $6.0M Larger Scale ANRO
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% -60.7% Higher Growth ANRO
Operating Margin (TTM)
Profitability
0.0% -858.2% Higher Margin ANRO
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-46.7% -182.8% Higher ROE ANRO
52-Week Range Position
Momentum
53% ($11–$37) 9% ($0–$1) Stronger Trend ANRO
Beta / 30D Volatility
Risk Regime
2.03β · 94% Vol 1.37β · 138% Vol Lower Realized Risk ANRO
Unified Institutional Score
Composite Signal
34.3 / 100 (SELL) 44.1 / 100 (HOLD) Higher Composite EVGN
Trailing 12M Revenue (USD)
Operating Scale
N/A $1.7M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A -67.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$80M ($301M Net Cash) -$11M ($6.5M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ANRO +16.74 pp
ANRO: +9.16% · EVGN: -7.58%
3M Horizon ANRO +14.8 pp
ANRO: -28.6% · EVGN: -43.4%
6M Horizon ANRO +76.1 pp
ANRO: +21.81% · EVGN: -54.29%
1Y Horizon ANRO +177.59 pp
ANRO: +105.7% · EVGN: -71.89%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ANRO vs EVGN. Trailing 12-month operating profitability (ANRO 0.0% vs EVGN -858.2%) and valuation multiples (ANRO N/M vs EVGN N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ANRO ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-46.7% · N/M
EVGN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.7M
Gross Margin-67.6%
Op. Margin-858.2%
ROE / Fwd P/E-182.8% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ANRO BREAKDOWN
58d in phase · OBV ACCUMULATION
Current IV 82.2%
IV Percentile 9th %ile
Put/Call OI Skew 0.04x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact ANRO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
EVGN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact EVGN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ANRO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.1B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
EVGN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $6.0M market capitalization and -858.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ANRO vs EVGN Key Questions & Quantitative Answers

As of Nov 17, 2026, Alto Neuroscience Inc. (ANRO) is the stronger overall head-to-head candidate over Evogene Ltd. (EVGN) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). ANRO carries a Unified Composite Score of 34.3/100 (SELL) at $24.91 (N/M Forward P/E, 0.0% operating margin), whereas EVGN carries 44.1/100 (HOLD) at $0.34 (N/M Forward P/E, -858.2% operating margin). Composite vs. Pillar Nuance: While EVGN currently prints a higher short-term Unified Composite Score (44.1/100 HOLD vs. ANRO 34.3/100 SELL), ANRO captures the overall institutional head-to-head verdict (6–1 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -858.2% operating margin) and revenue trajectory (+0.0% vs. -60.7% YoY). Technical & Structure Timing Caution: ANRO is currently in a Breakdown options structure phase (RSI 47.4); meanwhile EVGN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ANRO leads the Growth & Scale pillar: ANRO posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with EVGN at -60.7% YoY revenue growth and +0.0% YoY earnings growth on $1.7M TTM revenue (-67.6% gross margin, -858.2% operating margin). On trailing 12-month operating scale, ANRO generates N/A in USD-normalized revenue versus $1.7M for EVGN. In operating R&D and SG&A reinvestment, ANRO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for EVGN.

ANRO and EVGN trade at balanced relative valuation multiples. ANRO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas EVGN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ANRO (-46.7% ROE) versus EVGN (-182.8% ROE) capital efficiency.

In options market volatility and institutional positioning, ANRO carries 82.2% implied volatility (9th %ile, Compressed (<25th %ile)), a 0.04x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (2.03β · 94% Vol realized risk). By comparison, EVGN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.37β · 138% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.